

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. *)

Urovant Sciences Ltd.

(Name of Issuer)

Common shares, par value \$0.000037453 per share

(Title of Class of Securities)

G9381B 108

(CUSIP Number)

**Suite 1, 3rd Floor,
11-12 St. James's Square,
London SW1Y 4LB,
United Kingdom
+44 (117) 918-1293**

**With copies to:
Colin Diamond
Chang-Do Gong
White & Case LLP
1221 Avenue of the Americas
New York, NY 10020-1095
+1 (212) 819 8200**

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

October 1, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Name of Reporting Persons:
Roivant Sciences Ltd.
I.R.S. Identification Nos. of Above Persons (Entities Only):

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only

4. Source of Funds (See Instructions)
WC (see Item 3)

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization
Bermuda

7. Sole Voting Power
22,703,669 (see Item 5)

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

8. Shared Voting Power
0 (see Item 5)

9. Sole Dispositive Power
22,703,669 (see Item 5)

10. Shared Dispositive Power
0 (see Item 5)

11. Aggregate Amount Beneficially Owned by Each Reporting Person
22,703,669 (see Item 5)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11)
75.6% (see Item 5)

14. Type of Reporting Person (See Instructions)
CO

EXPLANATORY NOTE

This report on Schedule 13D (the “Schedule 13D”) of Roivant Sciences Ltd. (“Roivant” or the “Reporting Person”) relates to the common shares, par value \$0.000037453 per share (the “Common Shares”), of Urovant Sciences Ltd. (the “Issuer”). The Reporting Person was initially eligible pursuant to Section 13(d)(6)(B) of and Rule 13d-1(d) under the Securities Exchange Act of 1934, as amended, to file a report on Schedule 13G as a beneficial owner of more than five percent of the Common Shares before the Issuer’s initial public offering (the “IPO”). The Reporting Person is filing this Schedule 13D in lieu of a report on Schedule 13G because, as a result of its purchase of Common Shares in the IPO, the Reporting Person acquired beneficial ownership of more than 2% of the Common Shares during the preceding 12 months.

Item 1. Security and Issuer

This Schedule 13D relates to the Common Shares of the Issuer. The principal executive offices of the Issuer are located at Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom.

Item 2. Identity and Background

(a) Reporting Person (Roivant)

This Schedule 13D is filed by Roivant, an exempted limited company incorporated under the laws of Bermuda. The principal business address of Roivant is Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom.

Roivant is principally engaged in the business of forming and supporting companies engaged in drug development and commercialization. It partners with biopharmaceutical companies and academic institutions to ensure that medicines are rapidly developed and delivered to patients upon approval. Roivant also launches healthcare companies operating outside of traditional biopharmaceutical development.

Covered Persons

Roivant Covered Persons

Roivant has a board of directors (collectively, the “Roivant Covered Persons”). The principal business address of each of the Roivant Covered Persons is Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom. The name, present principal occupation and country of citizenship of each of the Roivant Covered Persons is set forth below, along with the principal business address of the employer of each of the Roivant Covered Persons.

<u>Name</u>	<u>Principal Business Address of Employer</u>	<u>Present Principal Occupation</u>	<u>Citizenship</u>
Andrew Lo	c/o Roivant Sciences Ltd., Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom	Charles E. and Susan T. Harris Professor, MIT Sloan School of Management; Director of the MIT Laboratory for Financial Engineering; Principal Investigator at the MIT Computer Science and Artificial Intelligence Laboratory	United States
Patrick Machado	c/o Roivant Sciences Ltd., Suite 1, 3rd Floor, 11-12 St. James’s Square, London SW1Y 4LB, United Kingdom	Chairman, Amaron Bio Pty. Ltd.; Director, Endocyte, Inc.; Director, Chimerix, Inc.; Director, SCYNEXIS, Inc.; Director, Adverum Biotechnologies, Inc.	United States

Keith Manchester, M.D.	444 Madison Avenue, 21 st Floor New York, New York 10022	Managing Director and Head of Life Sciences, QVT Financial LP	United States
Akshay Naheta	69 Grosvenor Street London X0 W1K3JP, United Kingdom	Partner, SoftBank Investment Advisers and Managing Director for Strategic Finance, Softbank Group	United Kingdom
Ilan Oren	1 Dexcel Street, Or Akiva, 3060000, Israel	Vice President, Business Development, Dexcel Pharma Technologies Ltd.	Israel
Vivek Ramaswamy	c/o Roivant Sciences Ltd., Suite 1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, United Kingdom	President and Chief Executive Officer, Roivant Sciences, Inc.	United States

Control Persons of Roivant

The following persons, which include shareholders of Roivant and their control persons, may be deemed to control Roivant within the meaning of Instruction C to Schedule 13D, due to the power of the shareholders under Roivant's internal governance documents to direct or cause the direction of the management and policies of Roivant:

- (i) SVF Investments (UK) Limited, a limited company organized under the laws of England and Wales ("SVF Investments"), SVF Holdings (UK) LLP, a limited liability partnership organized under the laws of England and Wales ("SVF Holdings"), SoftBank Vision Fund L.P., a limited partnership organized under the laws of Jersey ("SoftBank Vision Fund"), and SVF GP (Jersey) Limited, a limited company organized under the laws of Jersey ("SVF GP", and collectively with SVF Investments, SVF Holdings and SoftBank Vision Fund, "SoftBank");
- (ii) QVT Family Office Fund LP (f/k/a QVT Fund V LP), a Cayman Islands limited partnership ("QVT Family"), QVT Financial LP, a Delaware limited partnership ("QVT Financial"), QVT Financial GP LLC, a Delaware limited liability company ("QVT Financial GP"), and QVT Associates GP LLC, a Delaware limited liability company ("QVT Associates", and collectively with QVT Family, QVT Financial and QVT Financial GP, "QVT");
- (iii) Dexxon Holdings Ltd., incorporated under the laws of Israel ("Dexxon Holdings"), Dexcel Pharma Technologies Ltd., incorporated under the laws of Israel ("Dexcel Pharma"), and Dan Oren, a citizen of Israel (collectively with Dexxon Holdings and Dexcel Pharma, "Dexxon"); and
- (iv) Viking Global Investors LP, a Delaware limited partnership ("VGI"), VGP Global Performance LLC, a Delaware limited liability company ("VGP"), Viking Global Equities LP, a Delaware limited partnership ("VGE"), Viking Global Equities II LP, a Delaware limited partnership ("VGEII"), VGE III Portfolio Ltd., a Cayman Islands exempted company ("VGEIII"), Viking Long Fund GP LLC, a Delaware limited liability company ("VLFGP"), Viking Long Fund Master Ltd., a Cayman Islands exempted company ("VLFM"), Viking Global Opportunities GP LLC, a Delaware limited liability company ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC, a Delaware limited liability company ("Opportunities Portfolio GP"), and Viking Global Opportunities Illiquid Investments Sub-Master LP, a Cayman Islands exempted limited partnership ("Opportunities Fund", and together with VGI, VGP, VGE, VGEII, VGEIII, VLFGP, VLFM, Opportunities GP and Opportunities Portfolio GP, "Viking").

See Appendix A to this Schedule 13D for certain information regarding each of SoftBank, QVT, Dexxon and Viking and their directors and executive officers, as applicable. As set forth on Appendix A, the “Covered Persons” include the Roivant Covered Persons, the SoftBank Covered Persons, the QVT Covered Persons, the Dexxon Covered Persons and the Viking Covered Persons (each as defined in Appendix A).

- (b) The principal business address of each of Roivant, as the Reporting Person, and the Covered Persons is set forth in Item 2(a) above, including Appendix A.
- (c) The principal business and principal business address of Roivant, as the Reporting Person, is set forth in Item 2(a) above. Additionally, the present principal occupation of each of the Covered Persons and the name, principal business and address of the organizations in which such occupation is conducted is set forth in Item 2(a) above, including Appendix A.
- (d) During the last five years, Roivant has not been convicted, and to Roivant’s knowledge, none of the Covered Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) During the last five years, Roivant has not been a party, and to Roivant’s knowledge, none of the Covered Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction such that, as a result of such proceeding, such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) The place of organization of each of Roivant, as the Reporting Person, and the citizenship or place of organization, as applicable, of each of the Covered Persons is set forth in Item 2(a) above, including Appendix A.

Item 3. Source and Amount of Funds or Other Consideration

Prior to the Issuer’s IPO, which closed on October 1, 2018, Roivant was the Issuer’s sole shareholder, directly owning 20,025,098 Common Shares. In connection with the IPO, Roivant agreed to purchase 2,678,571 Common Shares at an IPO price of \$14.00 per share. Roivant acquired the Common Shares using cash on hand.

Item 4. Purpose of Transaction

To the extent required by Item 4, the information contained in Items 3 above and 6 below is incorporated herein by reference.

Roivant purchased the 2,678,571 Common Shares in the IPO for investment purposes and intends to review its investment in the Issuer on a continuing basis. As the majority shareholder of the Issuer, Roivant may have significant or controlling influence over various matters with respect to its investment in the Issuer under the Issuer’s Amended and Restated Bye-laws (the “Bye-laws”), including, among other things: (i) the election and removal of directors; (ii) decisions of the Issuer’s board of directors (the “Board”), via Roivant’s right in the Bye-laws to appoint directors to the Board, the requirements for a Board quorum and the voting power of such directors, as described in Item 6; (iii) issuances of equity; (iv) amendments to the Issuer’s memorandum of association or actions to annul such amendments, following any required action by the Board; (v) amendments to the Bye-laws following any required action by the Board; (vi) provided that Roivant beneficially owns 75% of the outstanding aggregate voting power of the Issuer, the approval of any merger, amalgamation, sale of assets or other major corporate transaction; (vii) modifications of the rights of the holders of the Common Shares; and (viii) calling a special general meeting of holders of Common Shares or action by written consent pursuant to the required vote. Additionally, certain Covered Persons may in the future be involved as directors or executive officers of the Issuer in reviewing and evaluating possible transactions involving the Issuer and identifying candidates to serve on the Board. Through its majority shareholder status and through affiliations with Covered Persons with managerial positions at the Issuer, Roivant may be involved in transactions of the sort described in clauses (a) through (j) of Item 4 of Schedule 13D.

Additionally, Roivant or subsidiaries of Roivant and the Issuer are party to several commercial agreements, including an information sharing and cooperation agreement, services agreements and an intellectual property transfer

agreement. Currently, Roivant has no plans in respect of these commercial agreements that would involve transactions of the sort described in clauses (a) through (j) of Item 4 of Schedule 13D, and such agreements do not otherwise relate to securities of the Issuer within the meaning of Item 6 of Schedule 13D. Roivant may from time to time, however, be involved in transactions of the sort described in clauses (a) through (j) of Item 4 of Schedule 13D in connection with these commercial arrangements. Other than as required by Items 4 or 6 of Schedule 13D, Roivant does not anticipate making any public disclosures in connection with its participation in routine transactions and activities of the Issuer, including under these commercial arrangements, separate and apart from relevant public disclosures by the Issuer.

Roivant may, from time to time, take such actions regarding its investment as it deems appropriate. These actions may include: (i) acquiring additional Common Shares and/or other equity, debt, notes, other securities or derivative or other instruments of the Issuer that are based upon or relate to the value of Common Shares (collectively, “Securities”) in the open market or otherwise, including in connection with business development transactions or financing commitments in relation thereto; (ii) disposing of any or all of their Securities in the open market or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D. In determining whether to carry out any of the above-mentioned actions, Roivant may consider factors such as the Issuer’s financial position and strategic direction, actions taken by the Issuer’s Board, price levels of the Common Shares, conditions in the securities market and general economic and industry conditions.

Other than as described in this Item 4, Roivant does not have current plans or proposals that relate to or that would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D. Roivant may, at any time, review or reconsider its position with respect to the Issuer and reserves the right to develop such plans or proposals.

Item 5. Interest in Securities of the Issuer

(a) Reporting Person (Roivant)

Roivant directly beneficially owns 22,703,669, or 75.6%, of the Common Shares, and has sole voting and dispositive power over such Common Shares. Roivant disclaims beneficial ownership in all Common Shares reported herein, except to the extent of Roivant’s respective pecuniary therein.

Covered Persons

Roivant Independent Directors and Shareholders

As disclosed on reports on Schedule 13D previously filed by them, certain of the Covered Persons may be deemed beneficial owners of the Common Shares directly owned by Roivant pursuant to arrangements in Roivant’s internal governance documents. These Covered Persons are not reporting persons on this Schedule 13D.

Following the appointment to Roivant’s board of directors of one or more directors meeting certain independence criteria (each, an “Independent Director” and, collectively, the “Independent Directors”), dispositions of the Common Shares require the approval of a majority of Roivant’s board of directors, including (i) at least two Independent Directors or, (ii) if there is only one independent director, that sole Independent Director. Andrew Lo and Patrick Machado are currently Independent Directors of Roivant. Additionally, SoftBank, QVT, Dexxon and Viking, voting unanimously, have the right to override certain decisions of the Roivant board of directors, including with respect to dispositions of Common Shares, in certain circumstances. Based on these arrangements, the Covered Persons set forth below may be deemed to share “dispositive power” and, therefore, beneficial ownership over the Common Shares directly owned by Roivant. Such persons do not have voting power over the Common Shares directly owned by Roivant.

- (i) Andrew Lo;
- (ii) Patrick Machado;
- (iii) SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP;
- (iv) QVT Family, QVT Financial, QVT Financial GP and QVT Associates;
- (v) Dexxon Holdings, Dexcel Pharma and Dan Oren; and

- (vi) VGI, VGP, VGE, VGE II, VGE III, VLFGP, VLFM, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

All share percentage calculations in this Schedule 13D are based on 30,025,098 Common Shares outstanding following the closing of the Issuer's IPO as reported in the Issuer's prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act"), on September 27, 2018, assuming no exercise of the 30-day option of the underwriters of the IPO to purchase additional Common Shares.

- (b) See rows 7-10 of the cover page to this Schedule 13D for information regarding Roivant's power to vote or direct the vote and its power to dispose or direct the disposition of the Common Shares. Such information for the Covered Persons, who are not reporting persons on this Schedule 13D, is set forth in Item 5(a).
- (c) Except as disclosed in this Schedule 13D, Roivant has not effected and, to Roivant's knowledge, none of the Covered Persons has effected any transactions in the Common Shares during the past 60 days.
- (d) Except as disclosed in this Schedule 13D, no person other than Roivant has the right to receive, or the power to direct the receipt of dividends from, the proceeds from the sale of the shares to which this Schedule 13D relates.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

To the extent required by Item 6, the information contained in Items 3, 4 and 5 above is incorporated herein by reference.

Governance Rights

Roivant possesses certain governance rights and obligations as shareholders of the Issuer under the Bye-laws.

Board Appointment Rights

Prior to the first date on which Roivant ceases to hold at least 25% of the aggregate voting power of the Issuer's issued and outstanding shares (the "Trigger Date"), the Board must consist of at least five and no more than seven directors, and Roivant is entitled to appoint two directors (the "Roivant Directors") to the Board and each committee of the Board, other than the audit committee. Additionally, until the Trigger Date, the chairperson of the Board will be a Roivant Director. The current Roivant Directors are Ms. Mrytle S. Potter, who serves as the chairperson of the Board, and Mr. Frank M. Torti, M.D.

Board Voting Rights

The Roivant Directors will have three votes for each matter presented to the Board or any committee, other than the audit committee, in contrast with the non-Roivant Directors, who will have one vote for each matter. Following the Trigger Date, the chairperson of the Board will be elected by members of the Board and each Roivant Director will have one vote for each matter presented to the Board or any committee. Each Roivant Director will serve a term as determined by Roivant, which will last one year if no such determination is made. The presence of Roivant Directors will be necessary to constitute a quorum for actions taken by the Board.

Board Removal and Vacancy Rights

Prior to the Trigger Date, only Roivant or the remaining Roivant Director may appoint an individual to fill a vacancy on the Board left by a Roivant Director, and only Roivant may remove a Roivant Director with or without cause. Following the Trigger Date, any director, including a Roivant Director, may be removed with or without cause by a majority of the aggregate voting power of the Issuer's issued and outstanding shares.

Registration Rights

Roivant and the Issuer are party to a registration rights agreement, dated July 7, 2018 (the “Registration Rights Agreement”), providing Roivant with certain rights to have its shares registered by the Issuer for resale under the Securities Act. The registration rights will expire upon the earliest of (i) September 26, 2023, which is five years after the effective date of the registration statement relating to the IPO, (ii) when Roivant may sell all of its shares using Rule 144 under the Securities Act during any three-month period or (iii) in the event of a change of control or liquidation of the Issuer.

If the Issuer proposes to register the offer and sale of any of its Common Shares under the Securities Act for its own account or for the account of other shareholders, Roivant will be entitled to certain “piggyback” registration rights allowing it to include its Common Shares in such registration, subject to certain underwriter cutbacks and other limitations. Additionally, Roivant may request that the Issuer register its Common Shares on Form S-3 to the extent that the Issuer is qualified to do so. Such request for registration on Form S-3 must cover securities with an aggregate offering price of at least \$5.0 million, before payment of underwriting discounts, commissions and transfer taxes. The Registration Rights Agreement contains customary indemnification provisions.

Lock-up Agreement

Roivant has entered into a lock-up agreement with the underwriters of the IPO, dated May 22, 2018 (the “Lock-up Agreement”), pursuant to which Roivant has agreed that, for a period of 180 days beginning on September 26, 2018, it will not, without the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares or such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to the registration of any Common Shares or any security convertible into or exercisable or exchangeable for Common Shares, or (iv) publicly announce any intention to do any of the foregoing.

The foregoing descriptions of the Bye-laws, the Registration Rights Agreement and the Lock-up Agreement do not purport to be complete and are qualified in their entirety by reference to the Bye-laws, the Registration Rights Agreement and the Lock-up Agreement, copies of which are filed Exhibits 7.01, 7.02 and 7.03, respectively, to this Schedule 13D and which are incorporated herein by reference.

Item 7. Materials to be Filed as Exhibits

Exhibit No.	Description
7.01	Amended and Restated Bye-laws of Urovant Sciences Ltd. (incorporated by reference to Exhibit 3.3 to Urovant Sciences Ltd.’s Registration Statement on Form S-1, filed with the SEC on July 13, 2018).
7.02	Registration Rights Agreement, dated as of July 7, 2018, between Roivant Sciences Ltd. and Urovant Sciences Ltd. (incorporated by reference to Exhibit 10.9 of Urovant Sciences Ltd.’s Registration Statement on Form S-1, filed with the SEC on July 13, 2018).
7.03	Form of Lock-up Agreement (included as Exhibit D to the Form of Underwriting Agreement between Urovant Sciences Ltd. and J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters listed therein, incorporated by reference to Exhibit 1.1 of Amendment No. 3 to Urovant Sciences Ltd.’s Registration Statement on Form S-1, filed on August 30, 2018).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 10, 2018

Roivant Sciences Ltd.

By: /s/ Marianne Romeo Dinsmore

Name: Marianne Romeo Dinsmore

Title: Authorized Signatory

APPENDIX A

As used in this Schedule 13D, the term “**Covered Persons**” refers to each of the Roivant Covered Persons, the SoftBank Covered Persons, the QVT Covered Persons, the Dexion Covered Persons and the Viking Covered Persons.

SoftBank Covered Persons

SVF Investments is a wholly owned subsidiary of SVF Holdings. SoftBank Vision Fund is the managing member of SVF Holdings. SVF GP is the general partner of Softbank Vision Fund. As such, each of SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP may be deemed to share beneficial ownership of the Common Shares directly owned by Roivant.

The principal executive offices of SVF Investments and SVF Holdings is 69 Grosvenor Street, London, United Kingdom W1K 3JP. The principal executive office of SVF GP and Softbank Vision Fund is Aztec Group House, 11-15 Seaton Place, St. Helier, Jersey JE4 0QH.

The principal business of SVF GP is the management and control of the business of the SoftBank Vision Fund. The principal business of the SoftBank Vision Fund is to engage in making investments in securities of public and private companies. The principal business of SVF Investments and SVF Holdings is to directly hold securities of public and private companies, as determined by SVF GP, via SoftBank Vision Fund.

Each of Jonathan Bullock, Rajeev Misra, Simon King and Robert David Milner is a managing director of SVF GP. Their principal business addresses, present principal occupations and countries of citizenship are set forth below. SVF Investments, SVF Holdings, SoftBank Vision Fund, SVF GP and such managing directors of SVF GP are referred to herein as the “**SoftBank Covered Persons**.”

Name	Principal Business Address	Present Principal Occupation	Citizenship
Jonathan Bullock	69 Grosvenor Street, London, United Kingdom W1K 3JP	Director	United Kingdom
Rajeev Misra	69 Grosvenor Street, London, United Kingdom W1K 3JP	Director	United Kingdom
Simon King	Aztec Group House 11-15 Seaton Place, St. Helier, Jersey JE4 0QH	Director	United Kingdom
Robert David Milner	Aztec Group House 11-15 Seaton Place, St. Helier, Jersey JE4 0QH	Director and Attorney	United Kingdom

QVT Covered Persons

QVT Financial acts as the investment manager of QVT Family. QVT Financial GP is the general partner of QVT Financial. QVT Associates is a general partner of QVT Family. As such, each of QVT Family, QVT Financial, QVT Financial GP and QVT Associates may be deemed to share beneficial ownership of the Common Shares directly owned by Roivant.

The registered office of QVT Family is 190 Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands. The principal executive offices of QVT Financial, QVT Financial GP and QVT Associates are located at 444 Madison Avenue, 21st Floor, New York, New York 10022.

The principal business of QVT Family, QVT Financial, QVT Financial GP and QVT Associates is investment management.

Daniel Gold, Nicholas Brumm, Arthur Chu and Tracy Fu are the managing members of QVT Financial GP and QVT Associates. Their principal business addresses (which are also the addresses of their principal employers), present principal occupations and countries of citizenship are set forth below. QVT Family, QVT Financial, QVT Financial GP and QVT Associates and such managing members of QVT Financial GP and QVT Associates GP are referred to herein as the “**QVT Covered Persons.**”

Name	Principal Business Address	Present Principal Occupation	Citizenship
Daniel Gold	QVT Financial LP 444 Madison Avenue, 21 st Floor New York, New York 10022	Investment Management	United States
Nicholas Brumm	QVT Financial LP 444 Madison Avenue, 21 st Floor New York, New York 10022	Investment Management	United States
Arthur Chu	QVT Financial LP 444 Madison Avenue, 21 st Floor New York, New York 10022	Investment Management	United States
Tracy Fu	QVT Financial LP 444 Madison Avenue, 21 st Floor New York, New York 10022	Investment Management	United States

Dexxon Covered Persons

Dan Oren is the sole shareholder of Dexxon Holdings and the President and Chief Executive Officer of Dexcel Pharma. As such, each of Dexxon Holdings, Dexcel Pharma and Dan Oren may be deemed to share beneficial ownership of the Common Shares directly owned by Roivant.

The principal business address of Dexxon Holdings, Dexcel Pharma and Dan Oren is 1 Dexcel Street, Or Akiva, 3060000, Israel.

Dexxon Holdings is principally engaged in the business of investing in pharmaceutical companies. Dexcel Pharma is a manufacturer and distributor of pharmaceutical products. The principal occupation of Dan Oren is acting as sole director of Dexxon Holdings and President and Chief Executive Officer of Dexcel Pharma.

Dexxon Holdings has no executive officers and its sole director is Dan Oren. The directors of Dexcel Pharma are Uri Oren, Ilan Oren and Yitzchak Harush, along with Dan Oren, who is also Dexcel Pharma’s President and Chief Executive Officer. The present principal occupation, principal business address and country of citizenship of each of Dan Oren and Ilan Oren is set forth in Item 2(a) of this Schedule 13D. The present principal occupation of each of Uri Oren and Yitzchak Harush is serving as a director of Dexcel Pharma. The present principal business address of each of Uri Oren and Yitzchak Harush is 1 Dexcel Street, Or Akiva, 30600000, Israel. Each of Uri Oren and Yitzchak Harush is a citizen of Israel. Dexxon Holdings, Dexcel Pharma, Dan Oren, Uri Oren, Ilan Oren and Yitzchak Harush are referred to herein as the “**Dexxon Covered Persons.**”

Viking Covered Persons

VGP is the general partner of VGE and VGE II and the investment manager of VGEIII. VLFGP is the investment manager of VLFM. Opportunities Portfolio GP is the general partner of Opportunities Fund. Opportunities GP is the sole member of Opportunities Portfolio GP.

Viking Global Equities III Ltd. (a Cayman Islands exempted company) invests substantially all of its assets through VGEIII. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate LP (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM.

VGI, which is an affiliate of VGP, VLFGP and Opportunities Fund GP, provides managerial services to VGE, VGE II, VGE III and VLFM and Opportunities Fund. Viking Global Partners LLC is the general partner of VGI.

Each of O. Andreas Halvorsen, a citizen of Norway, David C. Ott, a citizen of the United States, Rose S. Shabet, a citizen of the United States, is a member of the Executive Committee of Viking Global, VGP, VLFGP and Opportunities GP.

As a result, each of VGI, VGP, VGE, VGE II, VGE III, VLFGP, VLFM, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet may be deemed to share beneficial ownership of the Common Shares directly owned by Roivant.

VGI, VGP, VGE, VGE II, VGE III, VLFGP, VLFM, Opportunities GP, Opportunities Portfolio GP, Opportunities Fund, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are referred to herein as the **“Viking Covered Persons.”**

The principal business address of each of the Viking Covered Persons is 55 Railroad Avenue, Greenwich, Connecticut 06830, which is also the principal business address of the employers of O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

The principal business of VGI is to provide managerial services to related entities engaged in making or recommending investments in securities of public and private companies. The principal business of each of VGP, VLFGP, Opportunities GP and Opportunities Portfolio GP is to serve as the general partner or investment manager of related entities engaged in making or recommending investments in securities of public and private companies. The principal business of each of VGE, VGE II, VGE III, Opportunities Fund and VLFM is to engage in making investments in securities of public and private companies. The present principal occupation of O. Andreas Halvorsen is Chief Executive Officer of VGI. The present principal occupation of David C. Ott is Advisory Director of VGI. The present principal occupation of Rose S. Shabet is Chief Operating Officer of VGI.